Here Is My Top Stock Pick Among the Weight Loss Industry Leaders

Eli Lilly is set to further dominate the burgeoning weight loss drug market, projected to reach $95 billion by 2030, with the impending submission of its oral pill orforglipron for regulatory review by year-end, following positive Phase 3 data. This new candidate, offering convenience and manufacturing advantages over competitors, complements Lilly's existing blockbuster injectables, Mounjaro and Zepbound, which fueled a 38% Q2 revenue surge. With a robust pipeline including retatrutide and a valuation of 33x forward earnings, the company is strategically positioned for sustained leadership despite increasing competition.

Analysis

Eli Lilly (LLY) is solidifying its dominant position in the rapidly expanding weight loss drug market, which is projected by Goldman Sachs Research to grow to $95 billion by 2030. The company's current injectable drugs, Mounjaro and Zepbound, were the primary drivers of a 38% year-over-year revenue increase in the second quarter, underscoring intense market demand that previously led to product shortages. Lilly is strategically expanding its portfolio with the planned submission of orforglipron, an oral pill, for regulatory review by year-end. Despite its 12% weight loss efficacy being lower than the 15% from Lilly's injectable, orforglipron offers significant competitive advantages over Novo Nordisk's rival oral candidate, including no food or drink restrictions and lower manufacturing costs as a small molecule drug. Furthermore, Lilly's pipeline includes retatrutide, a Phase 3 candidate with potential for even greater efficacy. The company's forward P/E multiple has become more attractive, decreasing from over 60 last year to 33, suggesting a more favorable valuation relative to its growth prospects.

Key Decisions for Investors

• Given Eli Lilly's robust revenue growth, deep pipeline with near-term catalysts such as the orforglipron submission, and a more favorable valuation at 33x forward earnings, investors should consider the stock's potential for continued leadership in the high-growth weight loss market.
• It is crucial to monitor competitive developments, particularly the regulatory progress of Novo Nordisk's oral Wegovy and clinical data from emerging players like Viking Therapeutics and Amgen, as these could impact Lilly's long-term market share.
• Investors should watch for key pipeline milestones, including the regulatory review of orforglipron and Phase 3 data for retatrutide, as positive outcomes are critical to sustaining the company's growth trajectory and market dominance.